Factors Affecting Growth Velocity after Discontinuation of Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Central Precocious or Early Puberty

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 596-621-Pediatric Endocrinology /Steroids and Puberty
Clinical
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-608
Yun Jung Choi*, Shin Hee Kim, Won Kyoung Cho, Kyoung Soon Cho, So Hyun Park, Seung Hoon Hahn, Min-Ho Jung, Byung-Kyu Suh and Byung Churl Lee
The Catholic University of Korea, Seoul, South Korea
Purpose The purpose of this study was to analyze growth velocity (GV) after discontinuation of Gonadotropin-releasing hormone agonist (GnRHa) treatment in girls with central precocious puberty (CPP) or early puberty and to identify clinical or laboratory factors associated with changes in GV.

Method We analyzed clinical and laboratory data of 56 girls with CPP (n=43) or early puberty (n=13) who were treated with GnRHa. GV, height standard deviation score (SDS), pubertal stage, hormonal parameters, chronological age (CA) and bone age (BA) were evaluated.

Results GV during the first year after discontinuation of GnRHa (5.8±1.6 cm/yr) increased significantly compared to GV during the last year of treatment (4.9±1.1 cm/yr) (P=0.001). GV during the second year after discontinuation of treatment (5.8±1.9 cm/yr) was not different from GV during the first year. GV during the first year after discontinuation of treatment was positively correlated with mid-parenteral height SDS (r=0.419, P=0.002), height SDS for BA at discontinuation of treatment (r=0.443, P=0.001) and predictive adult height at discontinuation of treatment (r=0.317, P=0.024). GV during the first year after discontinuation of treatment was negatively correlated with CA at start of treatment (r=-0.339, P=0.011), BA at start of treatment (r=-0.381, P=0.004), peak LH/FSH (r=-0.527, P=0.001) and pubertal stage at start of treatment (r=-0.362, P=0.007). In multiple linear regression analysis, lower BA at start of treatment (β=-0.321, P=0.020) and higher height SDS for BA at discontinuation of treatment (β =0.933, P=0.006) were associated with higher GV during the first year after discontinuation of treatment.

Conclusions These data suggest that BA at start of treatment and height SDS for BA at discontinuation of treatment are factors predicting increase in GV during the first year after discontinuation of GnRHa treatment.

Nothing to Disclose: YJC, SHK, WKC, KSC, SHP, SHH, MHJ, BKS, BCL

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm